Roche Says Divarasib Cut Lung Cancer Death Risk 44% in Phase III Trial
Roche said its experimental drug divarasib reduced the risk of death by 44% versus existing treatments in a Phase III study of previously treated patients with KRAS G12C-mutated non-small cell lung cancer.
Swiss drugmaker Roche BX:RHO said on Sunday its experimental lung cancer drug divarasib reduced the risk of death by 44% compared with existing treatments in a phase III study.• Roche said patients with previously treated KRAS G12C-mutated non-small cell lung cancer who received divarasib had media…